---
title: "5-year iDFS After PET-Guided Chemotherapy De-escalation in HER2-Positive Early Breast Cancer (PHER"
id: "nature-0-5-year-outcomes-of-chemotherapy-de-escalation-in-her2-positive-early-breast"
canonical_url: "https://medichelpline.com/clinical-feed/nature-0-5-year-outcomes-of-chemotherapy-de-escalation-in-her2-positive-early-breast"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04723-w"
published_at: "2026-10-29T11:02:09.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# 5-year iDFS After PET-Guided Chemotherapy De-escalation in HER2-Positive Early Breast Cancer (PHER
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-0-5-year-outcomes-of-chemotherapy-de-escalation-in-her2-positive-early-breast
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04723-w)
- **Published At:** 2026-10-29T11:02:09.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The randomized phase 2 **PHERGain** trial tested an **18F-FDG-PET**-guided, **pCR**-adapted approach to omit chemotherapy in operable HER2-positive early breast cancer. - Female patients with HER2-positive stage I–IIIA tumors ≥1.5 cm were randomized to standard chemotherapy plus trastuzumab and pertuzumab (group A) or dual HER2 blockade without upfront chemotherapy (group B), with treatment adapted by PET response and surgical pCR status. - After two cycles of trastuzumab and pertuzumab ± endocrine therapy, PET responders in group B continued on the chemotherapy-free regimen; nonresponders or patients without pCR received chemotherapy at that point. - The trial previously reported a 3-year invasive disease-free survival (**iDFS**) of 94.3% in group B. - With median follow-up of 5.6 years, the prespecified secondary endpoint—5-year iDFS—was 89.5% (95% CI 85.7–93.4) for group B (n = 267). - Among **18F-FDG-PET** responders in group B who achieved **pCR** without chemotherapy (post-randomization subgroup, n = 86), 5-year iDFS was 92.4% (95% CI 86.7–98.5); investigators reported one distant recurrence in this subgroup. - The authors cautioned that the subgroup estimate is descriptive and not evidence of causal effect from omitting chemotherapy because it is defined post-randomization by PET response and pCR. - Exploratory circulating tumor DNA (**ctDNA**) analyses showed that detectable ctDNA at baseline or during treatment was associated with worse iDFS; conversely, **ctDNA** clearance correlated with higher **pCR** rates and improved long-term outcomes. - The study team concluded these data support the clinical validity of an **18F-FDG-PET**-guided, **pCR**-adapted de-escalation strategy and raised the possibility that **ctDNA** could refine treatment individualization; ClinicalTrials.gov identifier NCT03161353.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41591-026-04723-w#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Medicine](https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg) ](https://www.nature.com/nm) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-026-04723-w) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nm/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nm/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nm/news-and-comment) * [ Podcasts ](https://www.nature.com/nm/podcast) * [ Current issue ](https://www.nature.com/nm/current-issue) * [ Collections ](https://www.nature.com/nm/collections) * [Follow us on Facebook ](https://www.facebook.com/Nature-Medicine-193691346949/) * [Follow us on X ](https://twitter.com/naturemedicine) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nm/aims) * [ Journal Information ](https://www.nature.com/nm/journal-information) * [ Editors ](https://www.nature.com/nm/editors) * [ Journal Metrics ](https://www.nature.com/nm/journal-impact) * [ Research Cross-Journal Editorial Team ](https://www.nature.com/nm/research-cross-journal-editorial-team) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nm/reviews-cross-journal-editorial-team) * [ Statistical Advisory Panel ](https://www.nature.com/nm/statistics-advisory-panel) * [ Our publishing models ](https://www.nature.com/nm/our-publishing-models) * [ Editorial Values Statement ](https://www.nature.com/nm/editorial-values-statement) * [ Editorial Policies ](https://www.nature.com/nm/editorial-policies) * [ Content Types ](https://www.nature.com/nm/content) * [ Web Feeds ](https://www.nature.com/nm/web-feeds) * [ Contact ](https://www.nature.com/nm/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ Submission Guidelines ](https://www.nature.com/nm/submission-guidelines) * [ For Reviewers ](https://www.nature.com/nm/for-reviewers) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/nm/open-access-funding) * [Submit manuscript ](https://mts-nmed.nature.com/cgi-bin/main.plex) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) 1. [nature](https://www.nature.com/) 2. [nature medicine](https://www.nature.com/nm) 3. [articles](https://www.nature.com/nm/articles?type=article) 4. article 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial [ Download PDF ](https://www.nature.com/articles/s41591-026-04723-w.pdf) [ Download PDF ](https://www.nature.com/articles/s41591-026-04723-w.pdf) * Article * [Open access](https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research) * Published: 29 October 2026 # 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial * [José Manuel Pérez-García](https://www.nature.com/articles/s41591-026-04723-w#auth-Jos__Manuel-P_rez_Garc_a-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04723-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04723-w#Aff2) [na1](https://www.nature.com/articles/s41591-026-04723-w#na1), * [Javier Cortés](https://www.nature.com/articles/s41591-026-04723-w#auth-Javier-Cort_s-Aff1-Aff2-Aff3-Aff4) [ORCID: orcid.org/0000-0001-7623-1583](https://orcid.org/0000-0001-7623-1583)[1](https://www.nature.com/articles/s41591-026-04723-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04723-w#Aff2),[3](https://www.nature.com/articles/s41591-026-04723-w#Aff3),[4](https://www.nature.com/articles/s41591-026-04723-w#Aff4) [na1](https://www.nature.com/articles/s41591-026-04723-w#na1), * [Manuel Ruiz-Borrego](https://www.nature.com/articles/s41591-026-04723-w#auth-Manuel-Ruiz_Borrego-Aff5) [ORCID: orcid.org/0000-0002-1181-5622](https://orcid.org/0000-0002-1181-5622)[5](https://www.nature.com/articles/s41591-026-04723-w#Aff5), * [Agostina Stradella](https://www.nature.com/articles/s41591-026-04723-w#auth-Agostina-Stradella-Aff6)[6](https://www.nature.com/articles/s41591-026-04723-w#Aff6), * [Begoña Bermejo](https://www.nature.com/articles/s41591-026-04723-w#auth-Bego_a-Bermejo-Aff7-Aff8-Aff9)[7](https://www.nature.com/articles/s41591-026-04723-w#Aff7),[8](https://www.nature.com/articles/s41591-026-04723-w#Aff8),[9](https://www.nature.com/articles/s41591-026-04723-w#Aff9), * [Santiago Escrivá-de-Romaní](https://www.nature.com/articles/s41591-026-04723-w#auth-Santiago-Escriv__de_Roman_-Aff10) [ORCID: orcid.org/0000-0001-7816-7589](https://orcid.org/0000-0001-7816-7589)[10](https://www.nature.com/articles/s41591-026-04723-w#Aff10), * [Cristina Reboredo](https://www.nature.com/articles/s41591-026-04723-w#auth-Cristina-Reboredo-Aff11)[11](https://www.nature.com/articles/s41591-026-04723-w#Aff11), * [Cinta Albacar](https://www.nature.com/articles/s41591-026-04723-w#auth-Cinta-Albacar-Aff12) [ORCID: orcid.org/0000-0002-4144-3348](https://orcid.org/0000-0002-4144-3348)[12](https://www.nature.com/articles/s41591-026-04723-w#Aff12), * [Noelia Martínez-Jáñez](https://www.nature.com/articles/s41591-026-04723-w#auth-Noelia-Mart_nez_J__ez-Aff13)[13](https://www.nature.com/articles/s41591-026-04723-w#Aff13), * [Vega Iranzo](https://www.nature.com/articles/s41591-026-04723-w#auth-Vega-Iranzo-Aff14) [ORCID: orcid.org/0000-0001-6183-5173](https://orcid.org/0000-0001-6183-5173)[14](https://www.nature.com/articles/s41591-026-04723-w#Aff14), * [Nuria Ribelles](https://www.nature.com/articles/s41591-026-04723-w#auth-Nuria-Ribelles-Aff15)[15](https://www.nature.com/articles/s41591-026-04723-w#Aff15), * [Florence Dalenc](https://www.nature.com/articles/s41591-026-04723-w#auth-Florence-Dalenc-Aff16)[16](https://www.nature.com/articles/s41591-026-04723-w#Aff16), * [Aleix Prat](https://www.nature.com/articles/s41591-026-04723-w#auth-Aleix-Prat-Aff17-Aff18-Aff19) [ORCID: orcid.org/0000-0003-2377-540X](https://orcid.org/0000-0003-2377-540X)[17](https://www.nature.com/articles/s41591-026-04723-w#Aff17),[18](https://www.nature.com/articles/s41591-026-04723-w#Aff18),[19](https://www.nature.com/articles/s41591-026-04723-w#Aff19), * [Peter Schmid](https://www.nature.com/articles/s41591-026-04723-w#auth-Peter-Schmid-Aff20-Aff21) [ORCID: orcid.org/0000-0001-9817-5228](https://orcid.org/0000-0001-9817-5228)[20](https://www.nature.com/articles/s41591-026-04723-w#Aff20),[21](https://www.nature.com/articles/s41591-026-04723-w#Aff21), * [Geraldine Gebhart](https://www.nature.com/articles/s41591-026-04723-w#auth-Geraldine-Gebhart-Aff22)[22](https://www.nature.com/articles/s41591-026-04723-w#Aff22), * [Frederik Marmé](https://www.nature.com/articles/s41591-026-04723-w#auth-Frederik-Marm_-Aff23) [ORCID: orcid.org/0000-0002-6591-3367](https://orcid.org/0000-0002-6591-3367)[23](https://www.nature.com/articles/s41591-026-04723-w#Aff23), * [Serena Di Cosimo](https://www.nature.com/articles/s41591-026-04723-w#auth-Serena-Di_Cosimo-Aff24)[24](https://www.nature.com/articles/s41591-026-04723-w#Aff24), * [Sofia Braga](https://www.nature.com/articles/s41591-026-04723-w#auth-Sofia-Braga-Aff25)[25](https://www.nature.com/articles/s41591-026-04723-w#Aff25), * [Marco Colleoni](https://www.nature.com/articles/s41591-026-04723-w#auth-Marco-Colleoni-Aff26)[26](https://www.nature.com/articles/s41591-026-04723-w#Aff26), * [Gabriele Antonarelli](https://www.nature.com/articles/s41591-026-04723-w#auth-Gabriele-Antonarelli-Aff27-Aff28)[27](https://www.nature.com/articles/s41591-026-04723-w#Aff27),[28](https://www.nature.com/articles/s41591-026-04723-w#Aff28), * [Giulia Notini](https://www.nature.com/articles/s41591-026-04723-w#auth-Giulia-Notini-Aff1-Aff2-Aff29-Aff30)[1](https://www.nature.com/articles/s41591-026-04723-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04723-w#Aff2),[29](https://www.nature.com/articles/s41591-026-04723-w#Aff29),[30](https://www.nature.com/articles/s41591-026-04723-w#Aff30), * [Maria Gion](https://www.nature.com/articles/s41591-026-04723-w#auth-Maria-Gion-Aff4-Aff31)[4](https://www.nature.com/articles/s41591-026-04723-w#Aff4),[31](https://www.nature.com/articles/s41591-026-04723-w#Aff31), * [Juan José García-Mosquera](https://www.nature.com/articles/s41591-026-04723-w#auth-Juan_Jos_-Garc_a_Mosquera-Aff1-Aff32) [ORCID: orcid.org/0000-0001-5165-4168](https://orcid.org/0000-0001-5165-4168)[1](https://www.nature.com/articles/s41591-026-04723-w#Aff1),[32](https://www.nature.com/articles/s41591-026-04723-w#Aff32), * [Lucia Sanz](https://www.nature.com/articles/s41591-026-04723-w#auth-Lucia-Sanz-Aff4)[4](https://www.nature.com/articles/s41591-026-04723-w#Aff4), * [Elena Martinez-Garcia](https://www.nature.com/articles/s41591-026-04723-w#auth-Elena-Martinez_Garcia-Aff1)[1](https://www.nature.com/articles/s41591-026-04723-w#Aff1), * [Alba Meya](https://www.nature.com/articles/s41591-026-04723-w#auth-Alba-Meya-Aff1)[1](https://www.nature.com/articles/s41591-026-04723-w#Aff1), * [Derek Dustin](https://www.nature.com/articles/s41591-026-04723-w#auth-Derek-Dustin-Aff33)[33](https://www.nature.com/articles/s41591-026-04723-w#Aff33), * [Ana Amaya-Garrido](https://www.nature.com/articles/s41591-026-04723-w#auth-Ana-Amaya_Garrido-Aff1)[1](https://www.nature.com/articles/s41591-026-04723-w#Aff1), * [Jose Antonio Guerrero-Martínez](https://www.nature.com/articles/s41591-026-04723-w#auth-Jose_Antonio-Guerrero_Mart_nez-Aff1)[1](https://www.nature.com/articles/s41591-026-04723-w#Aff1), * [Daniel Alcalá-López](https://www.nature.com/articles/s41591-026-04723-w#auth-Daniel-Alcal__L_pez-Aff1)[1](https://www.nature.com/articles/s41591-026-04723-w#Aff1), * [Jose Rodríguez-Morató](https://www.nature.com/articles/s41591-026-04723-w#auth-Jose-Rodr_guez_Morat_-Aff1) [ORCID: orcid.org/0000-0002-8133-9983](https://orcid.org/0000-0002-8133-9983)[1](https://www.nature.com/articles/s41591-026-04723-w#Aff1), * [Leonardo Mina](https://www.nature.com/articles/s41591-026-04723-w#auth-Leonardo-Mina-Aff1)[1](https://www.nature.com/articles/s41591-026-04723-w#Aff1), * [Mario Mancino](https://www.nature.com/articles/s41591-026-04723-w#auth-Mario-Mancino-Aff1)[1](https://www.nature.com/articles/s41591-026-04723-w#Aff1) & * … * [Antonio Llombart-Cussac](https://www.nature.com/articles/s41591-026-04723-w#auth-Antonio-Llombart_Cussac-Aff1-Aff34-Aff35) [ORCID: orcid.org/0000-0003-4515-8293](https://orcid.org/0000-0003-4515-8293)[1](https://www.nature.com/articles/s41591-026-04723-w#Aff1),[34](https://www.nature.com/articles/s41591-026-04723-w#Aff34),[35](https://www.nature.com/articles/s41591-026-04723-w#Aff35) Show authors [_Nature Medicine_](https://www.nature.com/nm) (2026) [Cite this article](https://www.nature.com/articles/s41591-026-04723-w#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) ## Abstract PHERGain was a randomized, non-comparative phase 2 trial evaluating a positron 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET)-guided, pathological complete response (pCR)-adapted strategy to omit chemotherapy in HER2-positive early breast cancer. Female patients with HER2-positive stages I–IIIA operable breast cancer (tumor size ≥ 1.5 cm) were randomized to receive chemotherapy plus trastuzumab and pertuzumab (HP; group A) or HP ± endocrine therapy (group B). In group B, treatment was adapted according to 18F-FDG-PET response after two cycles and pCR, with chemotherapy administered to nonresponders or patients without pCR. We previously reported that this de-escalation approach revealed a 3-year invasive disease-free survival (iDFS) of 94.3% (95% confidence interval (CI): 90.9 to 96.8) in group B. Here we report the prespecified secondary endpoint, 5-year iDFS and exploratory circulating tumor DNA (ctDNA) findings. After a median follow-up of 5.6 years, the 5-year iDFS was 89.5% (95% CI: 85.7 to 93.4) in group B (_n_ = 267) and 92.4% (95% CI: 86.7 to 98.5) among 18F-FDG-PET responders achieving pCR without chemotherapy (_n_ = 86), with one distant recurrence. The latter estimate describes a long-term outcome in a post-randomization subgroup defined by 18F-FDG-PET response and pCR and should be interpreted as descriptive rather than as causal effects of omitting chemotherapy. Detectable ctDNA at baseline or during treatment was associated with inferior iDFS, whereas ctDNA clearance correlated with higher pCR rates and improved long-term outcomes. These findings continue to support the clinical validity of an 18F-FDG-PET-guided, pCR-adapted approach and suggest a potential role for ctDNA in refining treatment individualization. ClinicalTrials.gov identifier: [NCT03161353](https://clinicaltrials.gov/study/NCT03161353). ### Explore related subjects Discover the latest articles and news in related subjects. * [Breast cancer](https://www.nature.com/subjects/breast-cancer) * [Drug development](https://www.nature.com/subjects/drug-development) * [Targeted Therapies in HER2-Positive Breast Cancer](https://www.nature.com/subjects/targeted-therapies-in-her2-positive-breast-cancer) ## Main Human epidermal growth factor receptor 2-positive (HER2+) breast cancer constitutes a unique and molecularly heterogeneous breast cancer subtype, which is characterized by amplification of the _ERBB2_ /_HER2_ gene or overexpression of the HER2 protein, and accounts for approximately 15–20% of all cases[1](https://www.nature.com/articles/s41591-026-04723-w#ref-CR1 "Hudis, C. A. Trastuzumab—mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39–51 \(2007\)."),[2](https://www.nature.com/articles/s41591-026-04723-w#ref-CR2 "Villacampa, G. et al. HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis. Lancet Oncol. 26, 1100–1112 \(2025\)."). This tumor subtype has presented substantial outcome improvements since the implementation of HER2-targeted therapies[3](https://www.nature.com/articles/s41591-026-04723-w#ref-CR3 "Harbeck, N. et al. De-escalation strategies in human epidermal growth factor receptor 2 \(HER2-positive early breast cancer \(BC\): final analysis of the West German Study Group adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor–positive phase ii randomized trial—efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy \(ET\) versus trastuzumab plus ET. J. Clin. Oncol. 35, 3046–3054 \(2017\)."),[4](https://www.nature.com/articles/s41591-026-04723-w#ref-CR4 "Tolaney, S. M. et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N. Engl. J. Med. 372, 134–141 \(2015\)."),[5](https://www.nature.com/articles/s41591-026-04723-w#ref-CR5 "von Minckwitz, G. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380, 617–628 \(2019\)."),[6](https://www.nature.com/articles/s41591-026-04723-w#ref-CR6 "Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164–172 \(2014\)."),[7](https://www.nature.com/articles/s41591-026-04723-w#ref-CR7 "Gianni, L. et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer \(NeoSphere\): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 17, 791–800 \(2016\)."). These therapeutic advances have facilitated the design of de-escalation strategies in selected subgroups of patients with HER2+ early breast cancer (EBC). The neoadjuvant setting provides an ideal context for this approach, as pathological complete response (pCR) is a favorable prognostic factor at the individual level for long-term outcomes, including disease-free survival (DFS) and overall survival (OS). The PHERGain study (ClinicalTrials.gov identifier: [NCT03161353](http://clinicaltrials.gov/study/NCT03161353)) showed the feasibility of an 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET)-guided, pCR-adapted strategy to avoid chemotherapy in patients with HER2+ EBC undergoing neoadjuvant dual HER2 blockade with trastuzumab and pertuzumab. Patients with centrally confirmed HER2+, stages I–IIIA, invasive, operable breast cancer (≥1.5 cm tumor size), with at least one breast lesion evaluable using 18F-FDG-PET were randomized (1-to-4 ratio) to receive either docetaxel, carboplatin and trastuzumab and pertuzumab (standard treatment; group A) or trastuzumab and pertuzumab ± endocrine therapy (adaptive treatment; group B). In group B, study treatment was guided by the 18F-FDG-PET response after two cycles of trastuzumab and pertuzumab ± endocrine therapy, as well as by the pathological response at surgery. Patients who did not show an 18F-FDG-PET response, or who had an 18F-FDG-PET response but did not achieve a pCR, also received chemotherapy (docetaxel and carboplatin). The first primary endpoint, pCR, demonstrated that 37.9% of patients in the adaptive treatment arm who were classified as 18F-FDG-PET responders after two initial cycles of trastuzumab and pertuzumab, and continued with six additional cycles of the same chemotherapy-free regimen, obtained a pCR at surgery[8](https://www.nature.com/articles/s415
## Related Clinical Research

- [ERBB2 Activating Mutations Increase Trastuzumab Deruxtecan Activity in HER2-Nonamplified mBC](https://medichelpline.com/clinical-feed/pubmed-42714867.md) (DOI: 10.1158/1078-0432.CCR-26-0198)
- [Phase-space Geometry of NF-κB Networks Modulates Phenotypic Plasticity in Breast Cancer](https://medichelpline.com/clinical-feed/pubmed-43037823.md) (DOI: 10.1007/s11538-026-01797-y)
- [HER2-targeted antibody–molecular glue conjugate drives selective cyclin K degradation](https://medichelpline.com/clinical-feed/biorxiv-10-a-molecular-glue-degrader-antibody-conjugate-for-her2-targeted-cyclin-k.md)
- [Normalized membrane ratio of TROP2 predicts response to datopotamab deruxtecan in NSCLC](https://medichelpline.com/clinical-feed/nature-1-normalized-membrane-ratio-of-trop2-as-a-predictor-of-clinical-outcomes-with.md)
- [EHR-driven Analysis of Sequential ADC Orders in Breast Cancer Using Human-Guided Agentic AI](https://medichelpline.com/clinical-feed/medrxiv-18-human-guided-agentic-ai-for-end-to-end-ehr-research-sequential-antibody-drug.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.